Home
Products
Products

We are leaders in microbiome research, with a focus on probiotic strains, starter cultures, and the influence of beneficial microbial communities on diverse hosts, including humans, animals, and plants.
News
News

We actively participate in international probiotic industry seminars and conferences, sharing our research results and industry insights with leading experts and peers around the world.
- Company News
- Industry Insight
About Us
About Us

We are leaders in microbiome research, with a focus on probiotic strains, starter cultures, and the influence of beneficial microbial communities on diverse hosts, including humans, animals, and plants.
Founder
Founder

We actively participate in international probiotic industry seminars and conferences, sharing our research results and industry insights with leading experts and peers around the world.
- Dr. Frank Fang
Contact Us
Contact Us

We welcome the opportunity to connect with you, share more insights, explore potential partnerships, and work together to drive innovation and growth in the probiotic industry.
- Contact Us
- Join Us

Home > News > Company News > Wecare Probiotics Institute's Dr. JianGuo Zhu Delivers Keynote Speech at the 10th Intestinal Microbiome and Health Symposium

Wecare Probiotics Institute's Dr. JianGuo Zhu Delivers Keynote Speech at the 10th Intestinal Microbiome and Health Symposium

Shanghai, China (December 21, 2024) – At the recently concluded 10th Intestinal Microbiome and Health Symposium, Dr. JianGuo Zhu from Wecare Probiotics Institute delivered a compelling keynote speech titled "Screening and Process Optimization of Industrialized Functional Probiotic Strains." The symposium, held in Shanghai from December 20-21, brought together leading experts, researchers, and industry professionals to discuss the latest advancements and future trends in intestinal microbiome research.

Dr. Zhu's presentation delved into the challenges faced in the industrialization of functional probiotics, including the limitations of high-throughput screening platforms, process scaling, cost control, supply chain issues, and the lack of comprehensive one-stop services. To address these hurdles, Wecare Probiotics has established state-of-the-art research institutes in Suzhou, Wuhan, and Luoyang, focusing on strain development, process optimization, and clinical research.

Key Highlights of Wecare Probiotics' Work:

Extensive Strain Library: Wecare boasts a vast strain library of over 40,000 strains, equipped with advanced evaluation technologies to assess strain properties such as tolerance and adhesion.
Comprehensive Research Capabilities: The company has conducted numerous strain safety assessments and established various cell and animal models to evaluate probiotic functions in areas like gut health, oral health, and immune regulation.
Process Optimization: Wecare employs cutting-edge technologies such as high-throughput screening, AI-powered fermentation optimization, and WGS-based metabolic pathway analysis to streamline the process from strain development to mass production.
Advanced Manufacturing Facilities: With a global-leading intelligent manufacturing line, including large-scale fermenters, centrifuges, freeze-drying equipment, and extensive GMP cleanrooms, Wecare ensures the production of high-quality probiotic strains.
Clinical Validation: Wecare's WecLac® clinical strains, with a single dose of up to 600 billion CFU, have shown promising results in clinical studies and received positive feedback from attendees.

By addressing the critical pain points in the industry and leveraging advanced technologies, Wecare Probiotics is driving innovation and setting new standards for the production of high-quality probiotics. The company's commitment to scientific research, technological advancements, and a focus on human health positions it as a leader in the field of intestinal microbiome.

News View All